- Home
- EWTX vs TBLA Comparison
EWTX vs TBLA Comparison
Compare EWTX & TBLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- TBLA
- Stock Information
- Founded
- EWTX 2017
- TBLA 2007
- Country
- EWTX United States
- TBLA United States
- Employees
- EWTX N/A
- TBLA N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- TBLA Computer Software: Programming Data Processing
- Sector
- EWTX Health Care
- TBLA Technology
- Exchange
- EWTX Nasdaq
- TBLA Nasdaq
- Market Cap
- EWTX 1.5B
- TBLA 1.2B
- IPO Year
- EWTX 2021
- TBLA N/A
- Fundamental
- Price
- EWTX $13.03
- TBLA $3.69
- Analyst Decision
- EWTX Buy
- TBLA Strong Buy
- Analyst Count
- EWTX 9
- TBLA 4
- Target Price
- EWTX $39.89
- TBLA $4.50
- AVG Volume (30 Days)
- EWTX 892.5K
- TBLA 1.6M
- Earning Date
- EWTX 08-07-2025
- TBLA 08-06-2025
- Dividend Yield
- EWTX N/A
- TBLA N/A
- EPS Growth
- EWTX N/A
- TBLA N/A
- EPS
- EWTX N/A
- TBLA 0.04
- Revenue
- EWTX N/A
- TBLA $1,779,705,000.00
- Revenue This Year
- EWTX N/A
- TBLA $7.69
- Revenue Next Year
- EWTX N/A
- TBLA $6.15
- P/E Ratio
- EWTX N/A
- TBLA $92.60
- Revenue Growth
- EWTX N/A
- TBLA 16.63
- 52 Week Low
- EWTX $10.60
- TBLA $2.50
- 52 Week High
- EWTX $38.12
- TBLA $4.30
- Technical
- Relative Strength Index (RSI)
- EWTX 35.20
- TBLA 57.02
- Support Level
- EWTX $12.72
- TBLA $3.62
- Resistance Level
- EWTX $13.37
- TBLA $3.76
- Average True Range (ATR)
- EWTX 0.65
- TBLA 0.12
- MACD
- EWTX -0.16
- TBLA -0.01
- Stochastic Oscillator
- EWTX 24.22
- TBLA 72.06
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About TBLA Taboola.com Ltd.
Taboola.com Ltd is a technology company that powers recommendations across the Open Web with an artificial intelligence-based, algorithmic engine. It partners with websites, devices, and mobile apps, collectively referred to as digital properties, to recommend editorial content and advertisements on the Open Web. Geographically it serves Israel, the United Kingdom, Germany, France, Rest of the world whilst it generates the majority of its revenue from the United States.